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Abstract
Personalized medicine, otherwise called stratified or precision medicine, aims to better target intervention to the
individual to maximize benefit and minimize harm. This review discusses how diabetes aetiology, pathophysiology and
patient genotype influence response to or side effects of the commonly used diabetes treatments. C-peptide is a useful
biomarker that is underused to guide treatment choice, severe insulin deficiency predicts non-response to glucagon-like
peptide-1 receptor agonists, and thiazolidinediones are more effective in insulin-resistant patients. The field of
pharmacogenetics is now yielding clinically important results, with three examples outlined: sulphonylurea sensitivity in
patients with HNF1A maturity-onset diabetes of the young; sulphonylurea sensitivity in patients with Type 2 diabetes
with reduced function alleles at CYP2C9, resulting in reduced metabolism of sulphonylureas; and severe metformin
intolerance associated with reduced function organic cation transporter 1 (OCT1) variants, exacerbated by drugs that
also inhibit OCT1. Genome-wide approaches and the potential of other ‘omics’, including metagenomics and
metabolomics, are then outlined, highlighting the complex interacting networks that we need to understand before we
can truly personalize diabetes treatments.
Diabet. Med. 33, 712–717 (2016)
Personalized medicine: from art to science
The practice of clinical medicine teaches us to assess each
patient and, on the basis of their symptoms, signs and
targeted investigations, to develop a personalized manage-
ment plan. When we manage patients with diabetes, it is
clear that they represent a very diverse group of people,
spanning all ethnicities, the young to the old, the slim to the
morbidly obese, the insulin-deficient to the markedly insulin-
resistant. As clinicians we try to take into account these
differences when developing a personalized management
plan with our patients. This process of personalizing therapy
currently is often more of an art than a science.
The joint American Diabetes Association/European Asso-
ciation for the Study of Diabetes position statement for the
management of hyperglycaemia in Type 2 diabetes [1] does
move guidelines away from a step-by-step protocol-driven
approach and encourages us to consider a patient-centred
approach. In this position statement the efficacy and side
effects of each diabetes drug class are presented with a
recommendation that ‘choice is based on patient preferences
as well as various patient, disease, and drug characteristics,
with the goal being to reduce glucose concentrations while
minimizing side effects, especially hypoglycaemia’. This
approach is sensible, pragmatic and largely based on com-
mon sense, e.g. avoiding sulphonylureas in those who are
vulnerable to hypoglycaemia, or where hypoglycaemia
would be of considerable risk such as in lorry drivers or
scaffolders. Yet whilst common sense would suggest to avoid
a weight-gaining therapy in someone who is obese, thiazo-
lidinediones appear to be more effective in insulin-resistant
individuals; how much should this improvement in HbA1c be
balanced against the increased weight gain? We need
evidence to guide these decisions, which requires trials
specifically aimed to assess what drug is ‘best’ for an
individual.
In addition to phenotypic heterogeneity of patients with
diabetes, we see diversity in response to treatment or
outcome of disease, despite similarity in phenotype: why
does one person end up requiring insulin treatment within
3 years of diagnosis, and another phenotypically similar
person not progress to insulin for > 15 years? Why does one
person develop diabetic retinopathy and another not, despite
both having 20 years of good glycaemic control? Heritability
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studies are useful here, as they tell us how much of the
variability between individuals can be explained by genetic
differences. The FIND-eye study [2] reported a broad sense
heritability for diabetic retinopathy of ~27% and we have
recently reported heritability for glycaemic response to
metformin at ~34% [3]. Thus, a considerable percentage of
variability in patient response or outcome is ‘intrinsic’ to that
individual, and this may well not be apparent in their
phenotype.
For a truly personalized approach to management of
patients of diabetes we need: 1) to better understand how
clinical phenotypic variation alters response or outcome; 2) to
identifymolecular signatures (‘omics’) that improve our ability
to predict outcome; and 3) to establish that knowing 1 and 2
will lead to a change in patient management and improved
patient care and outcome. In this way we should be able to
capture at least some of the ‘art of medicine’ and provide a
scientific rationale and evidence for personalized care.
To personalize, stratify or be precise?
The field of personalized medicine is an area of ever-
changing terminology (Fig. 1). In 1995–2005, the ability to
personalize treatment was largely considered the realm of
pharmacogenetics, or pharmacogenomics (a term used to
express studies across the whole genome). After a surge in
pharmacogenetic/-omic studies during this time, the publi-
cation rate of articles in this area has largely increased in
line with the background population of published papers.
The concept of personalized medicine really took off during
2007/2008 and remains a popular term; however, as it
became apparent that it would be hard to truly individu-
alize or personalize treatment, the term ‘stratified medicine’
became popular, the concept being that subgroups or strata
of individuals should be treated differently from other
strata. The final twist came with the concept of ‘precision
medicine’, which describes the use of clinical and ‘omic’
characteristics to enable a more precise treatment, i.e. one
that is more accurate, with less error (or fewer side effects).
This term was slowly emerging before this year, but the
launch of the Precision Medicine Initiative in the USA by
President Obama in his state of the nations address in
January 2015 has made this a highly trending term in the
literature.
When considering all these terms, it is apparent that the
field of personalized/precision medicine is dominated at
present by cancer therapies, where there is the unique ability
to obtain tissue from the target tissue and to identify somatic
mutations that will enable therapy that only acts on the
cancer. In the last 10 years, 12 times more cancer studies
have been published than diabetes studies in this area. In the
present review, I will use the term ‘personalized’, and
highlight key developments in personalized medicine in
diabetes from the last 10 years, and how the field continues
to evolve, especially in molecular or ‘omic’ space. I will focus
on glycaemia in non-Type 1 diabetes, rather than other
aspects of care, and in particular on glycaemic response to
therapies.
Diabetes pathophysiology
In patients with Type 2 diabetes, for a given level of
glycaemia, some patients will have marked insulin resistance,
with robust but insufficient insulin secretion, while others
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will have very low insulin secretion but be very, but
insufficiently, insulin-sensitive. Given that the diabetes treat-
ments work to promote insulin secretion (sulphonylureas,
dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1
receptor agonists) or to promote insulin action (thiazolidine-
diones) or independently of the insulin secretion/sensitivity
axis (sodium-glucose cotransporter-2 inhibitors, metformin),
it would seem logical that these drugs would work well in
particular patient subgroups. Insulin secretagogues require
some preserved b-cell function to work. A recent study on
glucagon-like peptide-1 receptor agonists showed that
patients with Type 2 diabetes with severe insulin deficiency
(fasting C-peptide < 0.25 nmol/l) had markedly reduced
glycaemic response, with an HbA1c reduction of only
5.2 mmol/mol in this group compared with 15.2 mmol/mol
in those with preserved b-cell function [4]. Conversely,
thiazolidinediones have been reported to work more effec-
tively in obese insulin-resistant patients compared with
patients of normal weight [5]. There are surprisingly few
studies that have comprehensively assessed fasting C-peptide
or other measures of insulin secretion and sensitivity in
relation to response to diabetes therapies, and this would
seem a likely fruitful area for further study, as C-peptide is a
simple-to-measure biomarker that is a useful marker of
underlying disease pathophysiology.
Monogenic aetiology
Aetiologically there has been a tendency to treat all Type 2
diabetes as one overarching entity, yet we now know that it is
possible to dissect the aetiology of Type 2 diabetes, especially
when considering potential monogenic forms of diabetes
such as maturity-onset diabetes of the young (MODY) and
familial partial lipodystrophy. MODY caused by mutations
in the HNF1A gene is a very good example of how dissecting
the aetiology of diabetes leads to personalized treatment.
After case reports of sulphonylurea sensitivity in this patient
group, a randomized crossover trial of sulphonylureas and
metformin in patients with HNF1A MODY and patients
with Type 2 diabetes established that patients with this
subtype of MODY are exquisitely sensitive to sulphonylurea
treatment [6]. This most likely relates to the fact that the
defects in the b cell caused by HNF1A mutations are in
glycolysis and mitochondrial metabolism, and are therefore
largely bypassed by sulphonylurea treatment, which acts
downstream on the KATP channel. This work has resulted in
the successful transition off insulin treatment and improved
patient care for this subgroup of patients [7]; however, this
success highlights another challenge of personalized care:
implementation. It is now more than 10 years since this
result was published, yet some areas of the UK have very low
referral rates for molecular genetic testing in diabetes [8]
which must result in many patients being inappropriately
treated. A more systematic approach to detection of mono-
genic disease is required.
Drug disposition
For a drug to be effective it has to reach its site of action at a
sufficient concentration to elicit an effect. Pharmacogenetics
has long focused on potential for variation in genes involved
in drug transport and metabolism to alter drug concentra-
tions and subsequently to alter drug action and side effects.
For diabetes drugs the two most robust findings relate to the
effect of variation in cytochrome P450 2C9 (CYP2C9) and
sulphonylurea efficacy and the recent discovery that variation
in organic cation transporter 1 (OCT1) alters tolerance to
metformin.
Sulphonylureas are primarily inactivated in the liver by the
cytochrome P450 2C9 enzyme. Whilst most people have a
normal version of this enzyme, some carry reduced-function
polymorphisms in the gene encoding this enzyme, termed *2
and *3. In all, 6% of the population carry two reduced-
function polymorphisms and, as such, would be predicted to
inactivate sulphonylureas poorly. A GoDARTS study from
Tayside, UK, established that this 6% of the population with
loss of function of CYP2C9 are 3.44 times more likely to
achieve an HbA1c target < 53 mmol/mol (7%) [9]; however,
as might be expected, increased drug concentrations as a
result of poor sulphonylurea metabolism have also been
associated with increased risk of hypoglycaemia, albeit in
limited small studies [10,11]. It seems likely that these
patients would benefit from a personalized approach to
therapy, with lower starting doses of sulphonylurea.
A genotype-driven clinical trial is required to establish this
before it can be implemented into clinical care.
Metformin, is an organic cation, and hence its disposition
is largely influenced by the group of transporters called the
organic cation transporters. Most focus has been on the role
of genetic variation in OCT1 on metformin efficacy because
OCT1 has an established role in metformin uptake into the
liver [12]; however, there is little consensus on the impact of
this transporter on metformin response. OCT1 also has a
role in metformin transport across the intestinal wall and it
was hypothesized that it may play a role in metformin
intolerance. We have recently established that the 8% of
white Europeans who carry two reduced-function variants in
OCT1 are nearly twice as likely to develop severe metformin
intolerance as those who have normal function in OCT1
[13]. This finding has subsequently been replicated in a small
cohort with self reported mild metformin intolerance [14].
Interestingly, we also showed that co-prescribed drugs
increase risk of intolerance [13]. There are a number of
drugs (see list in Fig. 2) that inhibit OCT1 transport, and
whilst these have a small effect in their own right, the impact
of these drugs on metformin intolerance is much greater in
those who carry two reduced function OCT1 variants, with
this group having a fourfold greater risk of gastrointestinal
intolerance to metformin (Fig. 2). This means that
patients with metformin intolerance who are treated with
an OCT1-interacting drug should be trialed on an alternative
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drug if possible, the most common of these drugs being the
proton pump inhibitors; in such patients a trial of H2
receptor antagonists should be considered. If these results can
be validated in a clinical trial, then it may be possible to
consider a scenario where a lower metformin dose or a slow-
release preparation is used and co-prescribed medication
altered in the 8% of patients who carry the risk genotype.
Insights from genome-wide studies
The widespread introduction of low-cost genome-wide arrays
has enabled themove from the study of single candidate genes,
to the study of common variants across the whole genome.
This approach has particular utility when the mechanism of
action of a drug is uncertain, and hence a candidate gene
approach is difficult. Despite the widespread use of genome-
wide association studies (GWAS) for most traits and common
diseases, the application of GWAS to drug response has been
limited. Probably the best example of GWAS applied to drug
outcomes in conditions other than diabetes was the finding
that variants in SLCO1B1 (encoding the statin transporter
OATP1B1) increase the risk of statin-associated myopathy,
with 2% of the population who carried two c-alleles at
rs4140956 being 16 times more likely to develop severe
myopathy with simvastatin. The effect size meant that only 85
cases needed to be included and 90 controls.
The only reported GWAS for diabetes drug response has
been formetformin. As themechanismof action remainsmuch
debated, the hypothesis-free approach of a GWAS offered
considerable potential to gain insight into the molecular
mechanism of action of metformin. The GoDARTS and UK
Prospective Diabetes Study (UKPDS) metformin pharmaco-
genetics study group carried out a GWAS in ~1100 patients
treated with metformin [15]. In that study, one locus on
chromosome 11 was associated with metformin response,
with a P value = 1.9*107. This locus was subsequently
replicated in two independent cohorts, including the UKPDS,
with a combined overall P value = 2.9*10-9. This genetic
association has been subsequently replicated in additional
European cohorts [16] and a Chinese cohort [17], making this
the most robust metformin pharmacogenetic variant for
metformin efficacy to date. The locus on chromosome 11,
tagged by rs11212617, consists of a large LD block encom-
passing seven genes. There is considerable supporting litera-
ture to point to the ATM gene as the likely candidate at this
locus. ATM encodes a DNA damage protein that is faulty in
some cancers. Somatic recessive mutations in ATM cause
ataxia telangiectasia, a syndrome characterized in part by
increased risk of cancer and diabetes [18,19].Wehave recently
confirmed that patients with ataxia telangiectasia have
impaired glycaemia and insulin resistance, which supports
the hypothesis thatATMplays a key role in insulinmetabolism
[20]. The exact mechanism whereby variation in ATM or its
adjacent partner gene NPAT, alters metformin response is a
focus of ongoing work.
Beyond genomics
To date personalized medicine in diabetes, and indeed in most
diseases, has focused on DNA sequence variation; however,
this only captures a fraction of the overall complexity of
human variation. As technology continues to drive forward,
we are now moving into a field that is far more complex, that
takes into account tissue-specific epigenetics (epigenomics)
and gene expression (transcriptomics), and the integration of
this expression data with environmental and drug exposures
that can be captured on large-scale targeted and non-targeted
assays of metabolites (metabolomics) and proteins (pro-
teomics). There is also an increasing recognition of the role
the gut microbiome plays in metabolism, and in particular
drugmetabolism [21]; genetic sequencing approaches are now
increasingly used to identify the bacterial species present in the
gut and relate this to disease risk or drug exposure. These
approaches have not yet been applied to the study of drug
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outcome indiabetes but have been reported for other drugs and
outcomes. For example, in the field of pharmacometabolomics
(reviewed inKaddurah-Daouk et al. [22]), themetabotype has
been shown to alter treatment response to selective serotonin
re-uptake inhibitors [23]. The gutmicrobiomehasbeenknown
to affect drug disposition formany years. For example, 10%of
the population are colonized with the intestinal anaerobic
bacterium Eubacterium lentum, which metabolizes and inac-
tivates > 40% of ingested digoxin before it is absorbed [24];
the co-adminstration of antibiotics that disrupt this inactiva-
tion results in cardiotoxicity [25].
Intriguingly, metformin is recognized as playing an
increasing role in the gut [26] and has been recently shown
to alter the microbiome in a way that may account for at
least some of the intolerance and efficacy associated with
metformin treatment [27]. The study of the microbiome, and
associated host metabolome, in relation to metformin
response is, therefore, likely to be an area of increasing
interest. How this will translate into personalized therapy
will be interesting, but some studies have already assessed the
impact of a microbiome modulator on metformin intolerance
with some success [28].
Conclusions
All clinicians aim to practise personalized medicine, but to
date we are not armed with sufficient evidence to truly
personalize treatment, resulting in the need for an educated
guess or a trial-and-error approach. The modern era of
personalized medicine is moving towards identifying clinical
and molecular signatures than predict a therapeutic outcome,
reducing the uncertainty in treatment decisions, i.e. making
treatment more precise. We are however at the beginning of
this process, with only few robust examples of phenotype or
genotype guiding treatment choice. The recent technological
advances enable a much greater understanding of individual
variability that may alter outcome, but also vastly increase
the complexity of studies aiming to identify such predictive
biomarkers. It seems highly likely that the next 10 years will
deliver major advances in personalized medicine in diabetes;
what seems even more likely is that it will not be called
personalized or even precision medicine by then.
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